Articles

BioMarin Rare Disease Therapy Fails Phase 3: Key Takeaways for Pharma Teams

BioMarin Pharmaceutical's rare disease therapy failed to show clinical benefit in a Phase 3 trial, triggering a reassessment of R&D strategy and investor confidence. This article covers key takeaways, regulatory implications, and actionable insights for pharma business development and regulatory teams.

FDA's Future: Insights from Former Commissioner David Kessler

Former FDA Commissioner David Kessler, speaking at the STAT Breakthrough Summit West on May 19, 2026, expressed cautious optimism about the agency's ability to thrive despite recent high-profile departures and internal turmoil. This analysis distills his insights and outlines implications for pharmaceutical business development and regulatory strategy teams.

ASCO 2026: Ivonescimab HARMONi-6 OS Data

As Akeso prepares for a plenary presentation at ASCO 2026, ivonescimab's HARMONi-6 overall survival data will be closely watched. This article covers key takeaways, competitive implications, and next milestones for pharma teams and investors.

Biotech's Strategic Turning Point: Insights from Jeremy Levin

Jeremy Levin discusses the biotech industry's strategic turning point, highlighting key developments and their implications for pharmaceutical teams. The analysis underscores the imperative for pharma to embrace strategic partnerships and foster innovation to maintain a competitive edge.

Drug Discovery USA 2026: What to Expect

Drug Discovery USA 2026 in Cambridge, MA, will spotlight breakthrough drug launches and regulatory updates. This analysis covers key takeaways, implications for pharma teams, and answers to top industry questions.

Pfizer sharpens prostate cancer case with Talzenna win — oncology

Pfizer announced a Phase III win for Talzenna (talazoparib) plus Xtandi (enzalutamide) in metastatic castration-sensitive prostate cancer, setting up a potential broader label. This analysis covers the TALAPRO-3 results, implications for the prostate cancer treatment landscape, and key milestones for pharma teams and investors.

Explaining Unapproved Drugs to Payors: FDA Guidance Helps Pharma Avoid Pitfalls

The FDA has issued new guidance on how drug manufacturers can communicate information about unapproved drugs to payors, aiming to reduce legal risks. This article explains the key provisions, including what can and cannot be said about study results, and offers strategic insights for pharma teams.

AstraZeneca's Camizestrant: Navigating Divergent Regulatory Paths for Breast Cancer Treatment

AstraZeneca's breast cancer drug, camizestrant, faced a significant regulatory divergence with CHMP approval in Europe contrasting with an FDA rejection. This split highlights evolving global regulatory landscapes and presents key considerations for pharmaceutical business development and investment strategies.

MIT Funding Squeeze: Why Scientists Are Losing Heart

Structured plan for Why Optimistic Scientists Are Losing Heart: Insights from MIT

FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for generic eribulin mesylate injection. This approval offers a new therapeutic option for patients with pretreated metastatic breast cancer and unresectable or metastatic liposarcoma.

House BINSA Bill Targets China Biotech Deals

Structured plan for House bill aims to crack down on China biotech deals

Medical Education Diversity: URiM Workforce Gaps

While medical schools are admitting more diverse students, the number of practicing physicians from underrepresented backgrounds has not kept pace, creating systemic barriers. This gap has significant implications for pharmaceutical companies seeking to serve diverse patient populations.

Impact of CDER Leadership Changes on Pharma Strategy

Recent leadership shifts within the FDA's Center for Drug Evaluation and Research (CDER) signal potential alterations in regulatory priorities and drug approval processes. This analysis explores the strategic implications for pharmaceutical companies, business development teams, and investors.

ASGCT Annual Meeting 2026: Key Insights Guide

The ASGCT Annual Meeting 2026 is set to be the premier event for cell and gene therapy professionals. This live coverage will bring you the most significant advancements and industry insights.

Biotech's Future: Insights from Jeremy Levin

Structured plan for Biotech's Future: Insights from Jeremy Levin

PROTEUS Hormone Regimen in Prostate Cancer

Trump's Disloyalty Claims: Implications for Louisiana's Republican Primary

Structured plan for Trump's Disloyalty Claims: Implications for Louisiana's Republican Primary

The Hidden History of BPC-157: Unlocking Pharma Opportunities

Delve into the intriguing history of BPC-157, a peptide with significant regenerative medicine potential, and uncover its implications for pharmaceutical business development and investment strategies. Understand its research trajectory and market impact.

Eisai's Leqembi Sales Forecast: A Turning Point?

Structured plan for Eisai's Leqembi Sales Forecast: A Turning Point?

FDA Draft Aims to Cut Gene Therapy Repeat Testing

Structured plan for FDA seeks to cut repeat work for gene therapy developers